Skip to main navigation

Top Navigation

About Us
- Our Company
- Contact Us
Our Pipeline
- Pipeline
  - ZN-c3
  - ZN-c5
  - ZN-d5
  - ZN-e4
- Clinical Trials
Our Approach
- Integrated Discovery Engine
- Supporting Publications
Investors & Media
Careers

Investors/Media

Press Releases

Press Releases

Year

May 16, 2022

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

May 16, 2022

Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer

May 05, 2022

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

Apr 27, 2022

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

Apr 11, 2022

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

Apr 08, 2022

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

Mar 29, 2022

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

Mar 22, 2022

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

Mar 15, 2022

Stand Up to Cancer Announces $1 Million Donation From Zentalis Pharmaceuticals To Fund Targeted Cancer Therapy Research

Mar 09, 2022

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investors/Media

Investor Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
- SEC Filings
Corporate Governance
Investor Resources

Investor Contact

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

Privacy Policy
Terms of Use
Expanded Access Policy
Site Map

Copyright © 2022 Zentalis Pharmaceuticals. All Rights Reserved.